Wilding (MB102009) 2009

NCT00357370

1 Treatments

Studied treatment 10 mg dapagliflozin, or 20 mg dapagliflozin, plus OAD(s) and 50% of their daily insulin dose

Control treatment placebo

Concomitant treatments -

2 Patients

Patients patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding double-blind

Design -

Centers 26

Geographical area US, Canada

Sizes -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References
